Recombinant Human RECK Fc Chimera Protein, CF

When Recombinant Human RECK Fc Chimera (Catalog # 10309-RE) is immobilized at 2 μg/mL (100 μL/well), Recombinant Human TEM5/GPR124 His-tag (Catalog # 10206-TE) binds with an ED50 of 0.7‑5.6 μg/mL.

2 μg/lane of Recombinant Human RECK Fc Chimera (Catalog # 10309-RE) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing a band under reducing conditions at ~131 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human RECK Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human RECK Fc Chimera (Catalog # 10309-RE) is immobilized at 2 µg/mL (100 µL/well), Recombinant Human TEM5/GPR124 His-tag (Catalog # 10206-TE) binds with an ED₅₀ of 0.7-5.6 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human RECK protein
  

  Human RECK (Met1-Pro941) Accession # O95980	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: O95980
• N-terminal Sequence: Gly27
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 127 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 125-137 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human RECK Fc Chimera Protein, CF

• hRECK
• membrane-anchored glycoprotein (metastasis and invasion)
• RECK
• reversion-inducing-cysteine-rich protein with kazal motifs
• ST15
• ST15reversion-inducing cysteine-rich protein with Kazal motifs
• suppression of tumorigenicity 15 (reversion-inducing-cysteine-rich protein withkazal motifs)
• suppression of tumorigenicity 5 (reversion-inducing-cysteine-rich protein withkazal motifs)
• Suppressor of tumorigenicity 15 protein

Background

Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), also known as Suppressor of tumorigenicity 15 protein (ST15), is a 971 amino acid highly conserved protein that serves as an important mediator of tissue remodeling (1). The multi-domain protein includes hydrophobic regions at the N- and C-termini that correspond to a signal domain and GPI anchoring site, respectively (2). Internally, there are three serine protease inhibitor-like (SPI) domains and two regions with EGF-like repeats (2). The N-terminal region also contains a cysteine-rich domain essential for MMP (3) and Wnt7 binding (4, 5). RECK is normally expressed in all human and mammalian cells (2, 6) while undetectable or downregulated in malignant and cancer cells (1, 2). There is a strong correlation between expression of RECK and prognosis making it a prognostic marker target in several cancers including colorectal, breast, and pancreatic (1, 3, 7-9). Polymorphisms in RECK leads to increased cancer susceptibility (10). RECK's ability to bind several proteins confers complex functionality. RECK is known to bind and inhibit MMPs (1, 2, 11), interact with ADAMTS10 (12), modulate Notch signaling (13), promote p53 signaling (14) and act as a selective Wnt7 receptor through binding of Gpr124 (4). RECK acts as a tumor suppression gene by inhibiting angiogenesis, invasion, and metastasis through its role in the regulation and signaling within the extracellular matrix (1, 3, 6). Through its interaction with Wnt7, RECK promotes angiogenesis and regulates the blood-brain barrier in CNS by mediating canonical Wnt/beta-catenin signaling (4).

1. Alexius-Lindgren, M. et al. (2014) Anticancer Res. 34:3867.
2. Takahashi, C. et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95:13221.
3. Clark, J.C.M. et al. (2007) Cancer Mestast. Rev. 26:675.
4. Vallon, M. et al. (2018) Cell Reports. 25:339.
5. Cho, C. et al. (2019) Elife. 8:e47300.
6. Oh, J. et al. (2001) Cell. 107:789.
7. Takeuchi, T. et al. (2004) Clin. Cancer Res. 10:5572.
8. Zhang, G. et al. (2012) Cancer Sci. 103:1084.
9. Masui, T. et al. (2003) Clin. Cancer Res. 9:1779.
10. Chung, T.T. et al. (2012) PLoS ONE. 7:e33517.
11. Miki, T. et al. (2007) J. Biol. Chem. 282:12341.
12. Matsuzaki, T. et al. (2018) Biol. Open 7:bio033985.
13. Muraguchi, T. et al. (2007) Nat. Neurosci. 10:838.
14. Liu, Y. et al. (2018) J. Cell. Biochem. 119:3058.

Bioinformatics

• Uniprot:
  • O95980()